spectinomycin has been researched along with cycloserine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awuah, E; Barker, C; Brown, ED; Capretta, FA; Das, R; Gerritsma, DA; Lebert, J; Melacini, G; Pathania, R; Zlitni, S | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for spectinomycin and cycloserine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for spectinomycin and cycloserine
| Article | Year |
|---|---|
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
Topics: Anti-Bacterial Agents; Cell Division; Chromatography, Liquid; Cycloserine; Doxorubicin; Drug Resistance, Multiple; Escherichia coli; Escherichia coli Proteins; Fosfomycin; Genes, Bacterial; Genome, Bacterial; Genomics; Lipoproteins; Mass Spectrometry; Molecular Chaperones; Periplasmic Binding Proteins; Pseudomonas aeruginosa; Sulfamethoxazole; Suppression, Genetic; Trimethoprim | 2009 |